Triptorelin is a gonadotropin releasing hormone analogue that has been used in the clinical setting to treat advanced prostate cancer as part of a multi-faceted approach to androgen deprivation therapy. Similar to luteinizing hormone releasing hormone, triptorelin is a potent inhibitor of testosterone and estrogen synthesis when given in long-term, continuous dosing.